(Reuters) -Italian drug maker Recordati posted an 11.9% increase in its first-quarter net revenue on Thursday to 680.0 million euros ($767.52 million) and confirmed its guidance for 2025. Interest, taxes, depreciation and amortisation (EBITDA) rose to 270.2 million euros, while adjusted net income grew by 7.2% to 175.5 million euros. The company confirmed its guidance […]
Health
Drug maker Recordati’s Q1 revenue rises 11.9%, confirms 2025 guidance
Audio By Carbonatix
(Reuters) -Italian drug maker Recordati posted an 11.9% increase in its first-quarter net revenue on Thursday to 680.0 million euros ($767.52 million) and confirmed its guidance for 2025.
Interest, taxes, depreciation and amortisation (EBITDA) rose to 270.2 million euros, while adjusted net income grew by 7.2% to 175.5 million euros.
The company confirmed its guidance for 2025 and said it expects the group’s positive momentum to continue, as posted in its 2027 financial targets approved on April 28.
($1 = 0.8860 euros)
(Reporting by Laura Contemori, editing by Susan Fenton)